A detailed history of Victory Capital Management Inc transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 24,627 shares of ESPR stock, worth $57,380. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,627
Previous 22,210 10.88%
Holding current value
$57,380
Previous $49,000 18.37%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$1.61 - $2.73 $3,891 - $6,598
2,417 Added 10.88%
24,627 $40,000
Q2 2024

Aug 05, 2024

SELL
$1.84 - $3.24 $3,622 - $6,379
-1,969 Reduced 8.14%
22,210 $49,000
Q1 2024

May 03, 2024

BUY
$2.02 - $3.02 $18,141 - $27,122
8,981 Added 59.09%
24,179 $64,000
Q4 2023

Feb 05, 2024

BUY
$0.73 - $3.08 $2,597 - $10,958
3,558 Added 30.57%
15,198 $45,000
Q3 2023

Nov 06, 2023

BUY
$0.96 - $1.79 $1,317 - $2,455
1,372 Added 13.36%
11,640 $11,000
Q2 2023

Jul 27, 2023

BUY
$1.2 - $1.76 $12,321 - $18,071
10,268 New
10,268 $14,000
Q3 2021

Nov 02, 2021

SELL
$11.34 - $21.37 $197,202 - $371,624
-17,390 Closed
0 $0
Q2 2021

Aug 03, 2021

SELL
$19.4 - $28.71 $13,366 - $19,781
-689 Reduced 3.81%
17,390 $368,000
Q1 2021

May 04, 2021

SELL
$25.12 - $36.89 $20,497 - $30,102
-816 Reduced 4.32%
18,079 $507,000
Q4 2020

Feb 01, 2021

SELL
$24.2 - $35.76 $22,481 - $33,221
-929 Reduced 4.69%
18,895 $491,000
Q3 2020

Nov 09, 2020

SELL
$31.18 - $52.71 $227,302 - $384,255
-7,290 Reduced 26.89%
19,824 $737,000
Q2 2020

Aug 07, 2020

BUY
$30.04 - $51.31 $409,325 - $699,150
13,626 Added 101.02%
27,114 $1.39 Million
Q1 2020

May 04, 2020

SELL
$27.44 - $73.84 $38,992 - $104,926
-1,421 Reduced 9.53%
13,488 $425,000
Q4 2019

Feb 06, 2020

BUY
$35.4 - $59.82 $46,515 - $78,603
1,314 Added 9.67%
14,909 $889,000
Q4 2019

Feb 04, 2020

SELL
$35.4 - $59.82 $21,487 - $36,310
-607 Reduced 4.27%
13,595 $735,000
Q3 2019

Nov 12, 2019

BUY
$34.47 - $47.53 $480,132 - $662,045
13,929 Added 5102.2%
14,202 $521,000
Q4 2018

Feb 05, 2019

SELL
$36.99 - $59.11 $1,923 - $3,073
-52 Reduced 16.0%
273 $13,000
Q3 2018

Nov 01, 2018

BUY
$40.74 - $51.41 $1,751 - $2,210
43 Added 15.25%
325 $14,000
Q2 2017

Aug 07, 2017

BUY
N/A
282
282 $13,000

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $155M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.